News | May 05, 2023
Nouscom reaches clinical phase II using ProBioGen’s AGE1.CR.pIX production platform
Nous-209 has been developed using the Nouscom's viral vector platform
Nous-209 has been developed using the Nouscom's viral vector platform
From cancer research to diagnostic solutions
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Proposed combination enhances Pfizer’s position as a leading company in oncology
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Subscribe To Our Newsletter & Stay Updated
